| Project/Area Number |
15K10603
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Takada Hideki 名古屋市立大学, 大学院医学研究科, 研究員 (10747611)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
河合 憲康 名古屋市立大学, 大学院医学研究科, 准教授 (20254279)
安藤 亮介 名古屋市立大学, 医学(系)研究科(研究院), その他 (30381867)
戸澤 啓一 名古屋市立大学, 大学院医学研究科, 教授 (40264733)
内木 拓 名古屋市立大学, 大学院医学研究科, 講師 (50551272)
小林 大地 名古屋市立大学, 医学(系)研究科(研究院), 研究員 (80570704)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Kawai Noriyasu 名古屋市立大学, 大学院医学研究科腎・泌尿器科分野 (20254279)
|
|---|
| Research Collaborator |
Ando Ryosuke 名古屋市立大学, 大学院医学研究科腎・泌尿器科分野 (30381867)
Naiki Taku 名古屋市立大学, 大学院医学研究科腎・泌尿器科分野 (50551272)
Kobayashi Daichi 名古屋市立大学, 大学院医学研究科腎・泌尿器科分野, 研究員 (80570704)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | MCL / MCL thermotherapy / 免疫 / 浸潤性膀胱がん / Thermotherapy |
|---|
| Outline of Final Research Achievements |
As a new therapy that does not require surgical treatment, we developed thermotherapy (MCL Heat Therapy) using positively charged liposome-embedded magnetic nanoparticles (MCL) as a heating element, and prostate cancer We have reported the growth inhibitory effect of various cancers at the beginning. In that study, we found induction of strong antitumor immunity via MHC molecule of MCL Heat Therapy. In this study, we injected MCL bladder and irradiated with an alternating magnetic field to strengthen induction to Th1 and CTL and proved a significant tumor reduction effect. In addition, by administering anti-TGF-β antibody and anti-IL-6 antibody, induction of differentiation into Th-17, Treg was suppressed, induction to Th 1 was strengthened, and demonstrated stronger tumor reduction effect.
|
